title: Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.
abstract: OBJECTIVE
  We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent (18)F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41% using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS).
  
  
  RESULTS
  Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm(3). The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm(3)) and 60% in the high metabolic burden group (TMTV >550 cm(3), p = 0.04), and prediction of OS was even better (87% vs. 60%, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index.
  
  
  CONCLUSIONS
  Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
authors.affiliation: Nuclear Medicine and Lymphoid Malignancies Unit, Henri Mondor Hospital, Paris-Est University, 51 Ave. du Mal de Lattre, 94010, Créteil, France.
authors.forename: Myriam
authors.initials: M
authors.lastname: Sasanelli
authors.forename: Michel
authors.initials: M
authors.lastname: Meignan
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.forename: Alina
authors.initials: A
authors.lastname: Berriolo-Riedinger
authors.forename: René-Olivier
authors.initials: RO
authors.lastname: Casasnovas
authors.forename: Alberto
authors.initials: A
authors.lastname: Biggi
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Barry A
authors.initials: BA
authors.lastname: Siegel
authors.forename: Amanda F
authors.initials: AF
authors.lastname: Cashen
authors.forename: Pierre
authors.initials: P
authors.lastname: Véra
authors.forename: Hervé
authors.initials: H
authors.lastname: Tilly
authors.forename: Annibale
authors.initials: A
authors.lastname: Versari
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Itti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D049268:Positron-Emission Tomography; D015203:Reproducibility of Results; D014057:Tomography, X-Ray Computed; D047368:Tumor Burden; D055815:Young Adult
chemical_list: D019788:Fluorodeoxyglucose F18